Evidence map›Paper›PMID 30940999›Full record

Observational studyJournal of Korean medical science2019

A 6-year Prospective, Observational, Multi-Center Post-Marketing Surveillance of the Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine in Korea.

Hee-Jin Park, Sung Jin Kim, Rok Song, Jing Chen, Joon-Hyung Kim, Raghavendra Devadiga, Hee-Cheol Kang

Registry-linked trialOpen access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Journal of Korean medical science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01929291 (Assessment of Safety of GlaxoSmithKline), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01929291 completednot on this map

Assessment of Safety of GlaxoSmithKline (GSK) Biologicals' Combined Reduced Antigen Content Diphtheria-tetanus Toxoids and Acellular Pertussis Vaccine (dTPa), Boostrix When Administered According to the Approved Prescribing Information in Korea

TypeobservationalSponsorGlaxoSmithKlineRan2013 to 2016Enrolled682ConditionsDiphtheria-Tetanus-acellular Pertussis VaccinesArmsBoostrix, Safety data collection
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Observational
  5. Observational
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Hee-Jin ParkDepartment of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University, Seoul, Korea.ORCID https://orcid.org/0000-0003-0538-3517
Sung Jin KimGSK, Seoul, Korea.ORCID https://orcid.org/0000-0001-5054-8048
Jing ChenGSK, Singapore, Singapore.ORCID https://orcid.org/0000-0002-7611-4173
Joon-Hyung KimGSK, Rockville, MD, USA.ORCID https://orcid.org/0000-0002-6014-3543
Raghavendra DevadigaGSK, Bangalore, India.ORCID https://orcid.org/0000-0002-3224-6043
Hee-Cheol KangDepartment of Family Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-0309-7448
The Genetics Society of Korea · KRCHA University · KRGlaxoSmithKline (India) · INGlaxoSmithKline (United States) · USYonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIncidence of whooping cough is increasing in Korea. Since 2011, occurrence among adolescents and adults has risen putting vulnerable neonates at risk. National immunization guidelines now include Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) vaccination during pregnancy and as a cocooning strategy (i.e., vaccinating adults and adolescents in contact with neonates). This study assessed post-marketing Tdap (Boostrix

methodsThis open, non-comparative multi-center study was conducted over six years at 10 hospitals in Korea. Subjects received Tdap in normal clinical practice according to local prescribing information. All adverse events (AEs) were recorded, classified as expected or unexpected, and severity and relationship to Tdap were assessed.

resultsThe analysis included 672 Korean subjects (mean age, 44 years; range, 11-81), 451 were women and 211 were pregnant. Ninety subjects experienced 124 AEs (incidence 13.39%) of which six were serious AEs (SAEs) assessed as not related to vaccination, and 51 were non-SAEs related to vaccination (mostly administration site reactions). Overall 65/124 AEs were unexpected; the most common were 14 constipation, 5 dyspepsia, 4 common cold and 4 premature labor cases. One case of common cold was assessed as possibly related to vaccination. Pregnancy outcome was 'live infant, no apparent congenital anomaly' in 195 subjects (92.42%) or 'lost to follow-up' in 16 subjects.

conclusionTdap administration to Korean subjects ≥ 10 years, including pregnant women, for the prevention of diphtheria, tetanus and pertussis was shown to have a well-tolerated safety profile.

trial registrationClinicalTrials.gov Identifier: NCT01929291.

Indexed as

Product Surveillance, PostmarketingAdolescentAdultAgedChildDiphtheria-Tetanus-acellular Pertussis VaccinesFemaleGastrointestinal DiseasesHumansMaleMiddle AgedObstetric Labor, PrematurePregnancyProspective StudiesPruritusRepublic of KoreaDiphtheria-Tetanus-acellular Pertussis VaccinesKoreaPost Marketing SurveillanceSafetyTdap VaccineWhooping Cough

Identifiers

PMID30940999
PMCPMC6439203
OpenAlexW2925905129

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.